Fig. 5 | Signal Transduction and Targeted Therapy

Fig. 5

From: RBD-Fc-based COVID-19 vaccine candidate induces highly potent SARS-CoV-2 neutralizing antibody response

Fig. 5

Cross-neutralization activity against SARS-CoV and SARSr-CoV. a The RBD amino acid sequence of SARS-CoV-2, SARS-CoV, and bat-SARSr-CoV-WIV1. b, c Detection of SARS-CoV RBD-specific IgG in different dilutions of sera (b) and the IgG titer to SARS-CoV RBD (c). d–f Neutralization effects of total IgG from the indicated sera against SARS-CoV-2 (d), SARS-CoV (e) and WIV1 (f). Each point represents means ± s.e.m. from triplicate samples. *P < 0.05; **P < 0.01; ***P < 0.001

Back to article page